Abetis Plus tablet: Each coated tablet contains Olmesartan Medoxomil INN 20 mg and Hydrochlorothiazide BP 12.5 mg.
Abetis Plus ® is a combination preparation of Olmesartan Medoxomil and Hydrochlorothiazide, where Olmesartan is an Angiotensin II receptor antagonist (AT 1 subtype), and Hydrochlorothiazide is a thiazide diuretic. Olmesartan blocks the vasoconstrictor effects of Angiotensin II by selectively blocking the binding of Angiotensin II to the AT 1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for Angiotensin II synthesis. Hydrochlorothiazide affects the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of Hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. Co-administration of an Angiotensin II receptor antagonist (like-Olmesartan Medoxomil) tends to reverse the potassium loss associated with these diuretics (like–Hydrochlorothiazide).
Route: Oral
Adults:
Recommended starting dose is 1 tablet (20/12.5 mg) once daily. Titrate at 2–4 week intervals up to 2 tablets (40/25 mg) once daily.
Elderly:
Same dosage as adults.
Renal impairment:
No adjustment needed in mild to moderate impairment (CrCl 30–60 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min; loop diuretics preferred).
Pediatric:
Not recommended for children and adolescents under 18 years.
NSAIDs reduce antihypertensive and diuretic efficacy; lithium excretion reduced (monitor serum lithium levels); alcohol, barbiturates, and narcotics potentiate orthostatic hypotension; potassium supplements / ACE inhibitors alter serum potassium.
This combination preparation is contraindicated in patients who are hypersensitive to the active substances, to any of the excipients or to other sulfonamide-derived substances (since Hydrochlorothiazide is a sulfonamide-derived medicinal product).
Common: Vertigo, cough, back pain, rash, weakness, transient blurred vision, diarrhea, headache, urinary tract infection.
Overdose
Only limited information is available regarding Overdosage in humans although the most likely effect of overdosage is hypotension. If Overdosage is occurred, the patient should be carefully monitored and treatment should be symptomatic and supportive. The most common signs and symptoms of Hydrochlorothiazide overdose is electrolyte depletion i.e. – hypokalemia, hypochloremia, hyponatremia. Dehydration may also occur from excessive diuresis.
Category D (2nd/3rd trimesters), Category C (1st trimester). Causes fetal renal impairment and neonatal morbidity/death; discontinue immediately when pregnancy is detected. Lactation: Thiazides appear in human milk; discontinue nursing or discontinue drug.
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.